Bank of New York Mellon’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Bank of New York Mellon’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,046	Closed	-$14K	–	4583
2022 Q3	$14K	Sell	18,046 -50	-0.3%	-$105	﹤0.01%	4483
2022 Q2	$52K	Sell	18,096 -36,418	-67%	-$128K	﹤0.01%	4337
2022 Q1	$343K	Buy	54,514 +17,042	+45%	+$107K	﹤0.01%	3940
2021 Q4	$417K	Buy	37,472 +835	+2%	+$11.6K	﹤0.01%	3911
2021 Q3	$598K	Buy	36,637 +5,233	+17%	+$93.6K	﹤0.01%	3708
2021 Q2	$582K	Buy	31,404 +15,731	+100%	+$302K	﹤0.01%	3700
2021 Q1	$237K	Sell	15,673 -2,059	-12%	-$44.8K	﹤0.01%	4000
2020 Q4	$572K	Buy	+17,732	New	+$235K	﹤0.01%	3556

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of New York Mellon's CDAK Position: Q4 2022 in Review

Bank of New York Mellon sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2022, closing a stake of 18,046 shares — an estimated $14K sold.

Bank of New York Mellon first reported a position in CDAK in Q4 2020 and held it in 8 quarters. The position peaked at $598K in Q3 2021. 40 funds tracked by Wall St. Rank hold CDAK as of Q4 2022.

Bank of New York Mellon reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Bank of New York Mellon sold 18,046 Codiak BioSciences, Inc. Common Stock shares in Q4 2022, an estimated $14K.
Bank of New York Mellon first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Bank of New York Mellon's Codiak BioSciences, Inc. Common Stock position peaked at $598K in Q3 2021.
40 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.